Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b StudyJacqueline S. Garcia, Guillermo Garcia‐Manero, Andrew H. Wei et al.|Blood|2020Cited by 58
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Timothy P. Hughes, Carolyn Grove et al.|Blood|2024Cited by 24
Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Andrew Grigg et al.|Blood|2018Cited by 8
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2019Cited by 7
Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is RareDavid T Yeung, Timothy P. Hughes, Naranie Shanmuganathan et al.|Blood|2024Cited by 6